Therapeutic potential of lipase inhibitor orlistat in Alzheimer's disease

Medical Hypotheses

Volumn 73, Issue 5, 2009, Pages 662-663

  Du, Jing ^a   Wang, Zhao ^a  

^a Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL LIPASE; CHOLESTEROL; ENZYME INHIBITOR; LIPASE INHIBITOR; LIPOPROTEIN LIPASE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; ENZYME INHIBITION; FAT INTAKE; HUMAN; HYPERLIPIDEMIA; LIPID ABSORPTION; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ALZHEIMER DISEASE; ENZYME INHIBITORS; HUMANS; LACTONES; LIPASE; MODELS, THEORETICAL;

EID: 70349804928     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.04.046     Document Type: Article

References (38)

1. Small G.W., Rabins P.V., Barry P.P., Buckholtz N.S., DeKosky S.T., Ferris S.H., et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American association for geriatric psychiatry, the Alzheimer's association, and the American geriatrics society. JAMA 278 (1997) 1363-1371
2. Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci 5 Suppl. (2002) 1055-1057
3. Masliah E. Neuropathology: Alzheimer's in real time. Nature 451 (2008) 638-639
4. Reitz C., Tang M.X., Luchsinger J., and Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 61 (2004) 705-714
5. Kivipelto M., and Solomon A. Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence. Acta Neurol Scand 185 Suppl. (2006) 50-57
6. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322 (2001) 1447-1451
7. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kareholt I., Winblad B., et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62 (2005) 1556-1560
8. Burgess B.L., McIsaac S.A., Naus K.E., Chan J.Y., Tansley G.H., Yang J., et al. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 24 (2006) 114-127
9. Grundy S.M., and Denke M.A. Dietary influences on serum lipids and lipoproteins. J Lipid Res 31 (1990) 1149-1172
10. Hadvary P., Lengsfeld H., and Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 256 (1988) 357-361
11. Luthi-Peng Q., Marki H.P., and Hadvary P. Identification of the active-site serine in human pancreatic lipase by chemical modification with tetrahydrolipstatin. FEBS Lett 299 (1992) 111-115
12. Hadvary P., Sidler W., Meister W., Vetter W., and Wolfer H. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J Biol Chem 266 (1991) 2021-2027
13. Lowe M.E. Pancreatic triglyceride lipase and colipase: insights into dietary fat digestion. Gastroenterology 107 (1994) 1524-1536
14. Henness S., and Perry C.M. Orlistat: a review of its use in the management of obesity. Drugs 66 (2006) 1625-1656
15. Tonstad S., Pometta D., Erkelens D.W., Ose L., Moccetti T., Schouten J.A., et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 46 (1994) 405-410
16. Scheen A.J., Ernest P., and Letiexhe M.R. Pharmacy-clinics medication of the month. Orlistate (xenical). Rev Med Liege 54 (1999) 192-196
17. White L., Petrovitch H., Hardman J., Nelson J., Davis D.G., Ross G.W., et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia aging study participants. Ann NY Acad Sci 977 (2002) 9-23
18. Newman A.B., Fitzpatrick A.L., Lopez O., Jackson S., Lyketsos C., Jagust W., et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the cardiovascular health study cohort. J Am Geriatr Soc 53 (2005) 1101-1107
19. Whitmer R.A., Sidney S., Selby J., Johnston S.C., and Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64 (2005) 277-281
20. Launer L.J., Ross G.W., Petrovitch H., Masaki K., Foley D., White L.R., et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21 (2000) 49-55
21. Dufouil C., Richard F., Fievet N., Dartigues J.F., Ritchie K., Tzourio C., et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the three-city Study. Neurology 64 (2005) 1531-1538
22. Cukierman T., Gerstein H.C., and Williamson J.D. Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies. Diabetologia 48 (2005) 2460-2469
23. Bergmann C., and Sano M. Cardiac risk factors and potential treatments in Alzheimer's disease. Neurol Res 28 (2006) 595-604
24. Oksman M., Iivonen H., Hogyes E., Amtul Z., Penke B., Leenders I., et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23 (2006) 563-572
25. Studzinski C.M., Li F., Bruce-Keller A.J., Fernandez-Kim S.O., Zhang L., Weidner A.M., et al. Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP x PS1 knock-in mice. J Neurochem 108 (2009) 860-866
26. Rahman A., Akterin S., Flores-Morales A., Crisby M., Kivipelto M., Schultzberg M., et al. High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett 579 (2005) 6411-6416
27. Laitinen M.H., Ngandu T., Rovio S., Helkala E.L., Uusitalo U., Viitanen M., et al. Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Dement Geriatr Cogn Disord 22 (2006) 99-107
28. Eskelinen M.H., Ngandu T., Helkala E.L., Tuomilehto J., Nissinen A., Soininen H., et al. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiat 23 (2008) 741-747
29. Gargouri Y., Pieroni G., Moreau H., Ferrato F., Riviere C., Sauniere J.F., et al. Lipases of the digestive system. Reprod Nutr Dev 26 (1986) 1163-1176
30. Carriere F., Barrowman J.A., Verger R., and Laugier R. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology 105 (1993) 876-888
31. Zhi J., Melia A.T., Guerciolini R., Chung J., Kinberg J., Hauptman J.B., et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56 (1994) 82-85
32. Lookene A., Skottova N., and Olivecrona G. Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). Eur J Biochem 222 (1994) 395-403
33. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163 (2003) 463-468
34. Bisogno T., Cascio M.G., Saha B., Mahadevan A., Urbani P., Minassi A., et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761 (2006) 205-212
35. Baum L., Chen L., Masliah E., Chan Y.S., Ng H.K., and Pang C.P. Lipoprotein lipase mutations and Alzheimer's disease. Am J Med Genet 88 (1999) 136-139
36. Rebeck G.W., Harr S.D., Strickland D.K., and Hyman B.T. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 37 (1995) 211-217
37. Blain J.F., Aumont N., Theroux L., Dea D., and Poirier J. A polymorphism in lipoprotein lipase affects the severity of Alzheimer's disease pathophysiology. Eur J Neurosci 24 (2006) 1245-1251
38. Farooqui A.A., Liss L., and Horrocks L.A. Stimulation of lipolytic enzymes in Alzheimer's disease. Ann Neurol 23 (1988) 306-308